

## New generation of kits

VIDIA offers a new generation of IVD serological kits ELISA-VIDITEST with guaranteed stability and high sensitivity for a detection of specific antibodies IgG, IgA, IgM against specific antigens SARS-CoV-2 - Nucleocapsid Protein (NP) and Spike Protein (SP1). The determination of specific antibodies is available for both proteins separately. ELISA-VIDITESTs are intended for the qualitative and semiquantitative detection of antibodies in human serum and plasma.

| REF     | Product                  | Wells |
|---------|--------------------------|-------|
| ODZ-469 | anti-SARS-CoV-2 (NP) IgA | 96    |
| ODZ-470 | anti-SARS-CoV-2 (NP) IgG | 96    |
| ODZ-471 | anti-SARS-CoV-2 (NP) IgM | 96    |
| ODZ-472 | anti-SARS-CoV-2 (S1) IgA | 96    |
| ODZ-473 | anti-SARS-CoV-2 (S1) IgG | 96    |
| ODZ-474 | anti-SARS-CoV-2 (S1) IgM | 96    |
|         |                          |       |

## Test principle

**ELISA-VIDITEST** is a solid-phase immunoanalytical test. The specific antigens Nucleocapsid Protein (NP) or Spike Protein (S1) are fixed to each well of the microtiterstrips. Specific antibodies present in the patient's sample are bound during the first incubation step. After removing unbound material by washing, the presence of the specific antibodies is detected using anti-human IgA, IgG or IgM conjugate during the second incubation.

The unbound peroxidase conjugate is then removed and TMB substrate is added, resulting in the development of a blue colour in positive samples. The enzyme reaction is terminated by addition of the stop solution (colour change to yellow). The intensity of the yellow colour thus developed is proportional to the concentration of antibodies in the sample.

